Nanomedicine for Glioblastoma Therapy: Novel Insights and Future Perspectives
- 28 July 2026
- journal article
- review article
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 18 (4) , e70071
Abstract
Glioblastoma (GBM) remains one of the most aggressive primary brain tumors, with poor prognosis, high recurrence, and limited therapeutic options. Although substantial progress has been made in drug development, effective clinical translation is still constrained by inefficient delivery across the blood brain barrier (BBB) and blood brain tumor barrier (BBTB), insufficient tumor accumulation, intratumoral heterogeneity, acquired therapeutic resistance, and dose limiting systemic toxicity. Nanomedicine offers a promising strategy to address these barriers through tunable physicochemical properties, flexible surface functionalization, improved pharmacokinetics, and controllable drug release. In this review, we systematically summarize recent advances in nanomedicine enabled GBM therapy from four interrelated perspectives: the optimization of nanomaterial properties, the development of goal‐oriented targeting strategies, the rationalization of delivery routes, and the engineering of smart stimuli‐responsive nano‐systems. Rather than only cataloguing representative nanoplatforms, we emphasize how material parameters, biological targeting mechanisms, delivery routes, and release behaviors are mechanistically linked to BBB or BBTB penetration, tumor accumulation, therapeutic efficacy, and translational feasibility. Importantly, we also incorporate a key failure case analysis of representative clinical and preclinical studies, highlighting why promising nanotherapeutic concepts may fail because of inadequate intratumoral distribution, insufficient survival benefit, poor patient selection, manufacturing complexity, safety concerns, or impractical trial design. By integrating delivery mechanisms, cross platform comparison, translational barriers, and future optimization principles, this review provides a critical and forward looking framework for the rational design of precise, effective, and clinically translatable nanomedicine strategies for GBM treatment.Keywords
Funding Information
- Jiangsu Commission of Health (K2024052)
- Natural Science Foundation of Yangzhou Municipality (YZ2024246)
- Natural Science Foundation of Qinghai Province (2025‐ZJ‐955M)
This publication has 141 references indexed in Scilit:
- Engineering of Nanofibers Embedded with Targeted Nanoparticles Breaks Redox Levers for Glioblastoma TherapyAdvanced Functional Materials, 2024
- Effective and Targeted Human Orthotopic Glioblastoma Xenograft Therapy via a Multifunctional Biomimetic NanomedicineAdvanced Materials, 2023
- Transformable “Tubulin Traps” Interfere with Mitochondrial Autophagy and Promote the Elimination of GlioblastomaAdvanced Functional Materials, 2022
- Graphene Oxide Nanoscale Platform Enhances the Anti‐Cancer Properties of Bortezomib in Glioblastoma ModelsAdvanced Healthcare Materials, 2022
- Multifunctional STING‐Activating Mn3O4@Au‐dsDNA/DOX Nanoparticle for Antitumor ImmunotherapyAdvanced Healthcare Materials, 2020
- Cell Membrane‐Coated Magnetic Nanocubes with a Homotypic Targeting Ability Increase Intracellular Temperature due to ROS Scavenging and Act as a Versatile Theranostic System for Glioblastoma MultiformeAdvanced Healthcare Materials, 2019
- Association ofMGMTPromoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and TemozolomideJAMA Oncology, 2018
- Traceable Nanoparticles with Dual Targeting and ROS Response for RNAi‐Based Immunochemotherapy of Intracranial Glioblastoma TreatmentAdvanced Materials, 2018
- Biodistribution, Clearance, and Long‐Term Fate of Clinically Relevant NanomaterialsAdvanced Materials, 2018
- Dual‐Targeting Heparin‐Based Nanoparticles that Re‐Assemble in Blood for Glioma Therapy through Both Anti‐Proliferation and Anti‐AngiogenesisAdvanced Functional Materials, 2016